IL6R and Castleman disease: TCZ, a monoclonal antibody targeting human IL-6R, that is approved for treatment of rheumatoid arthritis, Castleman’s disease, juvenile idiopathic arthritis39, and newly used for treatment of cytokine release syndrome caused by CAR-T cell therapy40 or COVID-19 infection41 has gained momentum in the recent few years.